Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan P van Meerbeeck

Showing results (121-130 of 190) with videos related to

Pageof 19
Sort By:
International Journal for Quality in Health Care : Journal of the International Society for Quality in Health Care|March 6, 2018
Quality of care and variability in lung cancer management across Belgian hospitals: a population-based study using routinely available dataFrance Vrijens, Cindy De Gendt, Leen Verleye, et al.
American Journal of Respiratory and Critical Care Medicine|January 16, 2010
Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesotheliomaKevin Hollevoet, Kristiaan Nackaerts, Joël Thimpont, et al.
European Journal of Cancer (Oxford, England : 1990)|August 2, 2011
A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03)Rabab M Gaafar, Veerle F Surmont, Giorgio V Scagliotti, et al.
Lung Cancer (Amsterdam, Netherlands)|January 9, 2026
Multi-omic screening for pleural mesothelioma in Asbestos-Exposed Populations: A literature review and RecommendationsKathleen Zwijsen, Ellen Heirwegh, Eline Schillebeeckx, et al.
The European Respiratory Journal|December 25, 2014
Estimation of post-operative forced expiratory volume by functional respiratory imagingAnnelies Janssens, Wim Vos, Cedric Van Holsbeke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2005
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of CanadaJan P van Meerbeeck, Rabab Gaafar, Christian Manegold, et al.
Oncoimmunology|February 16, 2017
Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesotheliomaElly Marcq, Vasiliki Siozopoulou, Jorrit De Waele, et al.
Critical Reviews in Oncology/Hematology|April 30, 2015
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysisGiuseppe Bronte, Christian Rolfo, Francesco Passiglia, et al.
European Journal of Cancer (Oxford, England : 1990)|August 27, 2014
Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: an individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer Lung Cancer Group studies and an independent study validationBaktiar Hasan, Laurent Greillier, Athanasios Pallis, et al.
Acta Chirurgica Belgica|April 13, 2017
Malignant pleural mesothelioma: single-institution experience of 101 patients over a 15-year periodAndreas Domen, Christophe De Laet, Wies Vanderbruggen, et al.
Pageof 19

Showing results (121-130 of 190) with videos related to

Sort By:
Pageof 19
International Journal for Quality in Health Care : Journal of the International Society for Quality in Health Care|March 6, 2018
Quality of care and variability in lung cancer management across Belgian hospitals: a population-based study using routinely available dataFrance Vrijens, Cindy De Gendt, Leen Verleye, et al.
American Journal of Respiratory and Critical Care Medicine|January 16, 2010
Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesotheliomaKevin Hollevoet, Kristiaan Nackaerts, Joël Thimpont, et al.
European Journal of Cancer (Oxford, England : 1990)|August 2, 2011
A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03)Rabab M Gaafar, Veerle F Surmont, Giorgio V Scagliotti, et al.
Lung Cancer (Amsterdam, Netherlands)|January 9, 2026
Multi-omic screening for pleural mesothelioma in Asbestos-Exposed Populations: A literature review and RecommendationsKathleen Zwijsen, Ellen Heirwegh, Eline Schillebeeckx, et al.
The European Respiratory Journal|December 25, 2014
Estimation of post-operative forced expiratory volume by functional respiratory imagingAnnelies Janssens, Wim Vos, Cedric Van Holsbeke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2005
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of CanadaJan P van Meerbeeck, Rabab Gaafar, Christian Manegold, et al.
Oncoimmunology|February 16, 2017
Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesotheliomaElly Marcq, Vasiliki Siozopoulou, Jorrit De Waele, et al.
Critical Reviews in Oncology/Hematology|April 30, 2015
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysisGiuseppe Bronte, Christian Rolfo, Francesco Passiglia, et al.
European Journal of Cancer (Oxford, England : 1990)|August 27, 2014
Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: an individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer Lung Cancer Group studies and an independent study validationBaktiar Hasan, Laurent Greillier, Athanasios Pallis, et al.
Acta Chirurgica Belgica|April 13, 2017
Malignant pleural mesothelioma: single-institution experience of 101 patients over a 15-year periodAndreas Domen, Christophe De Laet, Wies Vanderbruggen, et al.
Pageof 19